Breaking News

Daiichi Sankyo, AstraZeneca Enter New $6B Global ADC Alliance

To jointly develop and commercialize DS-1062, a TROP2 directed DXd antibody drug conjugate in Phase I for non-small cell lung cancer and breast cancer.

By: Contract Pharma

Contract Pharma Staff

Daiichi Sankyo Co., Ltd. has entered into a global development and commercialization agreement with AstraZeneca for Daiichi’s DS-1062, a TROP2 directed DXd antibody drug conjugate (ADC), currently in Phase I development for non-small cell lung cancer (NSCLC) and triple negative breast cancer (TNBC). The companies will jointly develop and commercialize DS-1062 worldwide, except in Japan where Daiichi will maintain exclusive rights. Daiichi Sankyo will manufacture and supply DS-1062. This ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters